Gainers
- NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 14.5% to $0.53 during Tuesday's after-market session. The company's market cap stands at $14.0 million.
- Eargo (NASDAQ:EAR) shares moved upwards by 13.38% to $0.96. At the close, Eargo's trading volume reached 591.8K shares. This is 59.2% of its average volume over the last 100 days. The company's market cap stands at $37.6 million.
- Cabaletta Bio (NASDAQ:CABA) stock moved upwards by 12.17% to $1.29. The company's market cap stands at $37.3 million.
- Unity Biotechnology (NASDAQ:UBX) stock rose 11.22% to $0.68. At the close, Unity Biotechnology's trading volume reached 598.9K shares. This is 167.3% of its average volume over the last 100 days. The market value of their outstanding shares is at $46.8 million.
- SCWorx (NASDAQ:WORX) shares increased by 9.67% to $0.68. The company's market cap stands at $7.7 million.
- Mustang Bio (NASDAQ:MBIO) stock moved upwards by 9.24% to $0.63. The market value of their outstanding shares is at $64.9 million.
Losers
- iSpecimen (NASDAQ:ISPC) shares declined by 10.5% to $2.05 during Tuesday's after-market session. The market value of their outstanding shares is at $18.0 million.
- Purple Biotech (NASDAQ:PPBT) stock declined by 6.12% to $2.15. The company's market cap stands at $38.4 million.
- Atreca (NASDAQ:BCEL) stock fell 5.83% to $2.1. The company's market cap stands at $81.0 million.
- Lucid Diagnostics (NASDAQ:LUCD) stock fell 5.35% to $2.3. The market value of their outstanding shares is at $87.7 million.
- Protagonist Therapeutics (NASDAQ:PTGX) stock fell 5.09% to $8.03. At the close, Protagonist Therapeutics's trading volume reached 126.7K shares. This is 9.0% of its average volume over the last 100 days. The company's market cap stands at $390.7 million.
- Precipio (NASDAQ:PRPO) stock declined by 5.09% to $1.12. The market value of their outstanding shares is at $25.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
